Danaher Appoints New Leaders to Enhance Life Sciences and Drive Innovation Forward
- Greg Milosevich is appointed Executive Vice President for Life Sciences, emphasizing Danaher's commitment to innovation and health enhancement.
- Martin Stumpe joins as Chief Technology and AI Officer to lead Danaher's digital transformation and AI adoption in healthcare.
- These leadership changes reflect Danaher's dedication to scientific excellence and addressing global health challenges through advanced technologies.
Danaher Corporation Strengthens Leadership in Life Sciences with Key Executive Appointments
Danaher Corporation, a leader in life sciences and diagnostics, announces significant changes in its executive leadership that underscore its commitment to innovation and operational excellence. Effective July 1, 2025, Greg Milosevich steps into the role of Executive Vice President for the Life Sciences business, bringing with him a wealth of experience from his tenure within the company. Having served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021, Milosevich is well-positioned to drive the strategic vision of this vital sector. His promotion not only recognizes his accomplishments over the past four years but also aligns with Danaher’s overarching goal of enhancing human health through advanced technologies.
Milosevich's journey at Danaher began in 2010 following the acquisition of Molecular Devices, which has shaped his extensive understanding of the life sciences landscape. His previous roles at Beckman Coulter Life Sciences and Sciex have equipped him with a versatile skill set that is crucial for leading the Life Sciences division. President and CEO Rainer Blair emphasizes Milosevich’s results-driven approach and customer focus, traits that resonate with the principles of the Danaher Business System. This leadership transition comes at a time when the company aims to further consolidate its position in the life sciences industry, which is increasingly reliant on sophisticated technologies for rapid diagnostics and therapeutic developments.
In addition to Milosevich's appointment, Danaher announces the hiring of Martin Stumpe as Chief Technology and AI Officer, effective October 1, 2025. This role is critical in spearheading Danaher’s digital transformation initiatives, particularly in the adoption of artificial intelligence across its operations. Stumpe, who has previously served as the Chief Data and AI Officer, possesses a deep understanding of AI's potential in revolutionizing healthcare. His expertise, honed through significant positions at Tempus and Google, will be instrumental in enhancing scientific discovery and improving clinical outcomes. Blair’s endorsement of Stumpe as a visionary leader reflects Danaher's strategic focus on leveraging cutting-edge technologies to solve pressing health challenges.
Both appointments signal Danaher’s dedication to scientific excellence and continuous improvement as it seeks to enhance the quality of life globally. With a workforce of 63,000 associates, the company remains committed to addressing significant health challenges through innovation and technological advancements, laying a foundation for a more sustainable future. As Danaher continues to evolve, these leadership changes are expected to drive the company’s mission forward, ensuring it remains at the forefront of the life sciences industry.
